4 patents
Utility
Immunotherapy Compounds and Methods
13 Oct 22
An immunotherapy compound includes an NK cell engaging domain, an NK activating domain and a targeting domain.
Daniel A. VALLERA, Jeffrey S. MILLER, Martin FELICES, Martin SCHROEDER
Filed: 15 Sep 20
Utility
Use and Composition for Treating Myasthenia Gravis and Other Myasthenic Syndromes
19 Feb 20
The present invention describes the use of a 5HT3-antagonist, in combination with pyridostigmine, to facilitate the symptomatic treatment of mammalian subjects, and particularly humans, dogs, and cats, suffering from a myasthenic syndrome, notably myasthenia gravis, by providing a therapeutically effective pyridostigmine bromide daily dose without the typical adverse effects.
Kathleen E. CLARENCE-SMITH
Filed: 7 Jan 18
Utility
Neostigmine Combination and Compositions
1 Jan 20
The present invention describes the use of a 5HT3-antagonist, in combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis or other myasthenic syndromes by providing a therapeutically effective neostigmine bromide or methylsulfate daily dose that attenuates or even abrogates the dose-limiting gastrointestinal adverse effects of neostigmine.
Kathleen CLARENCE-SMITH
Filed: 22 Jan 18
Utility
Composition of Matter and Use Thereof for Preventing and Treating Motion Sickness
4 Dec 19
Motion sickness in a mammalian subject, in particular, a human, may be prevented or treated by administering to a mammalian, a transdermal device system releasing oxybutynin or one of its enantiomers, such as (R)-oxybutynin.
Kathleen E. CLARENCE-SMITH
Filed: 28 Dec 17
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first